Finance

Beta
Lists
LDZA:FRA
Aspen Pharmacare Holdings Ltd
€7.40
-1.33%
(-0.100) 1D
Jun 5, 8:06:07 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for LDZA...
Open
€7.40
High
€7.40
Low
€7.40
Mkt. cap
66.13B
Avg. vol.
20.00
Volume
0.00
52-wk high
€7.75
52-wk low
€4.50
No. of employees
9K
Open
€7.40
High
€7.40
Low
€7.40
Mkt. cap
66.13B
Avg. vol.
20.00
Volume
0.00
52-wk high
€7.75
52-wk low
€4.50
No. of employees
9K
News stories
From sources across the web
Profile
Aspen Pharmacare Holdings Limited is a public multinational pharmaceutical company headquartered in uMhlanga, South Africa. Founded in 1997, it listed on the Johannesburg Stock Exchange in 1998, and purchased South African Druggists in 1999 before expanding into international markets. Currently the largest pharmaceutical company in Africa through aggressive mergers and expansion, with major manufacturing sites in locations such as Gqeberha in South Africa, Bad Oldesloe in Germany, Notre-Dame-de-Bondeville in France, and Oss, Netherlands, Aspen is known for manufacturing and distributing branded pharmaceuticals as well as generic HIV/AIDS antiretrovirals and cancer medications. Among other products, Aspen has also been involved in manufacturing the Janssen COVID-19 vaccine through "fill and finish", and has the rights to sell the product under its own brand name Aspenovax. The company's revenue in 2022 was R38.6 billion. In 2016 Aspen was fined for high prices on cancer drugs, and after an investigation Aspen committed to reduce prices for 5 years in the European Union. Wikipedia
About Aspen Pharmacare Holdings Ltd
CEOStephen Saad
Employees9.34K
Founded1850
HeadquartersDurban, KwaZulu-Natal, South Africa
SectorPharmaceutical industry
Previous reportsAll values in ZAR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in ZAR
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
10.70B
10.70B
8.54B
8.54B
Cost of goods sold
6.40B
6.40B
4.81B
4.81B
Cost of revenue
6.40B
6.40B
4.81B
4.81B
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
2.79B
2.79B
2.17B
2.17B
Operating expense
2.75B
2.75B
2.82B
2.82B
Total operating expenses
9.15B
9.15B
7.63B
7.63B
Operating income
1.55B
1.55B
910.00M
910.00M
Other non operating income
-150.00M
-150.00M
-9.50M
-9.50M
EBT including unusual items
-1.65B
-1.65B
577.50M
577.50M
EBT excluding unusual items
1.12B
1.12B
577.50M
577.50M
Income tax expense
81.50M
81.50M
144.50M
144.50M
Effective tax rate
-4.93%
-4.93%
25.02%
25.02%
Other operating expenses
-39.50M
-39.50M
643.50M
643.50M
Net income
-1.74B
-1.74B
736.00M
736.00M
Net profit margin
-16.22%
-16.22%
8.62%
8.62%
Earnings per share
-
-
-
-
Interest and investment income
93.00M
93.00M
83.50M
83.50M
Interest expense
-445.50M
-445.50M
-426.50M
-426.50M
Net interest expenses
-352.50M
-352.50M
-343.00M
-343.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.79B
1.79B
1.39B
1.39B
Gain or loss from assets sale
11.00M
11.00M
-
-
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more